Clinical trials: Norovirus Acute Gastroenteritis

Gastroenteritis

Bivalent Norovirus Vaccine Study

• Completed
• Age: 18 to 85 years
• Phase 1
• Vaccines
• Results posted

Randomized, multi-site, dose-escalation study of the safety and immunogenicity of four dosage levels of Intramuscular (IM) Norovirus Bivalent VLP Vaccine adjuvanted with MPL and Al(OH)3 compared to controls.

Trial name

NCT01168401

Testing

NoV GI.1/GII.4 Bivalent VLP Vaccine, Saline

Where

3 sites in United States

Volunteers

102 people, healthy volunteers welcome

Sponsor

Takeda